How to overcome surfactant dysfunction in meconium aspiration syndrome?

Respiratory Physiology and Neurobiology

Volumn 187, Issue 1, 2013, Pages 58-63

  Mokra, Daniela ^a   Calkovska, Andrea ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Meconium aspiration syndrome; Pulmonary surfactant; Surfactant dysfunction

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ARTIFICIAL LUNG SURFACTANT; BILIRUBIN; BUDESONIDE; CHOLESTEROL; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEME; ILOPROST; LOPRINONE; LUNG SURFACTANT; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A2; PLASMA PROTEIN; POLYMER;

DRUG EFFICACY; HUMAN; HYPERCAPNIA; LEUKOCYTE ACTIVATION; LUNG DISEASE; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE ACTIVATION; MECONIUM; MECONIUM ASPIRATION; OXIDATIVE STRESS; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SURFACTANT DYSFUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFANT, NEWBORN; INFLAMMATION; MECONIUM ASPIRATION SYNDROME; PULMONARY SURFACTANTS;

EID: 84877920594     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2013.02.030     Document Type: Review

References (52)

1. Bae C.W., Takahashi A., Chida S., Sasaki M. Morphology and function of pulmonary surfactant inhibited by meconium. Pediatric Research 1998, 44:187-191.
2. Calkovska A., Sun B., Curstedt T., Renheim G., Robertson B. Combined effects of high-frequency ventilation and surfactant therapy in experimental meconium aspiration syndrome. Acta Anaesthesiologica Scandinavica 1999, 43:135-145.
3. Calkovska A., Some M., Linderholm B., Johansson J., Curstedt T., Robertson B. Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biology of the Neonate 2005, 88:101-108.
4. Calkovska A., Mokra D., Drgova A., Zila I., Javorka K. Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome. European Journal of Pediatrics 2008, 167:851-857.
5. Cleary G.M., Antunes M.J., Cieselka D.A., Higgins S.T., Spitzer A.R., Chander A. Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997, 100:998-1003.
6. Cockshutt A.M., Weitz J., Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990, 29:8424-8429.
7. Dargaville P.A. Innovation in surfactant therapy I: surfactant lavage and surfactant administration by fluid bolus using minimally invasive techniques. Neonatology 2012, 101:326-336.
8. Dargaville P.A., Mills J.F. Surfactant therapy for meconium aspiration syndrome: current status. Drugs 2005, 65:2569-2591.
9. de Beaufort A.J., Bakker A.C., van Tol M.J.D., Poorthuis B.J., Schrama A.J., Berger H.M. Meconium is a source of pro-inflammatory substances and can induce cytokine production in cultured A549 epithelial cells. Pediatric Research 2003, 54:491-495.
10. De Luca D., Minucci A., Tripodi D., Piastra M., Pietrini D., Zuppi C., Conti G., Carnielli V.P., Capoluongo E. Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates. Intensive Care Medicine 2011, 37:1158-1165.
11. Dehority W., Lu K.W., Clements J., Goerke J., Pittet J.F., Allen L., Taeusch H.W. Polyethylene glycol-surfactant for lavage lung injury in rats. Pediatric Research 2005, 58:913-918.
12. Diemel R.V., Snel M.M., Van Golde L.M., Putz G., Haagsman H.P., Batenburg J.J. Effects of cholesterol on surface activity and surface topography of spread surfactant films. Biochemistry 2002, 41:15007-15016.
13. Findlay R.D., Taeusch H.W., Walther F.J. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996, 97:48-52.
14. Fuchimukai T., Fujiwara T., Takahashi A., Enhorning G. Artificial pulmonary surfactant inhibited by proteins. Journal of Applied Physiology 1987, 62:429-437.
15. Geiger R., Kleinsasser A., Meier S., Neu N., Pajk W., Fischer V., Treml B., Stein J.I., Loeckinger A. Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Medicine 2008, 34:368-376.
16. Hallman M., Glumoff V., Rämet M. Surfactant in respiratory distress syndrome and lung injury. Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology 2001, 129:287-294.
17. Hentschel R., Jorch G. Acute side effects of surfactant treatment. Journal of Perinatal Medicine 2002, 30:143-148.
18. Higgins S.T., Wu A.M., Sen N., Spitzer A.R., Chander A. Meconium increases surfactant secretion in isolated rat alveolar type II cells. Pediatric Research 1996, 39:443-447.
19. Hilgendorff A., Rawer D., Doerner M., Tutdibi E., Ebsen M., Schmidt R., Guenther A., Gortner L., Reiss I. Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. Intensive Care Medicine 2003, 29:2247-2254.
20. Holm B.A., Wang Z., Notter R.H. Multiple mechanisms of lung surfactant inhibition. Pediatric Research 1999, 46:85-93.
21. Kääpä P., Kytölä J., Soukka H., Ahotupa M. Human meconium has potent antioxidative properties. Biology of the Neonate 1997, 72:71-75.
22. Larsson M., Nylander T., Keough K.M., Nag K. An X-ray diffraction study of alterations in bovine lung surfactant bilayer structures induced by albumin. Chemistry and Physics of Lipids 2006, 144:137-145.
23. Lopez-Rodriguez E., Echaide M., Cruz A., Taeusch H.W., Perez-Gil J. Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids. Biophysical Journal 2011, 100:646-655.
24. Lotze A., Mitchell B.R., Bulas D.I., Zola E.M., Shalwitz R.A., Gunkel J.H. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. Journal of Pediatrics 1998, 132:40-47.
25. Lu K.W., Goerke J., Clements J.A., Taeusch H.W. Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatric Research 2005, 58:206-210.
26. Lu K.W., Robertson B., Taeusch H.W. Dextran or polyethylene glycol added to Curosurf for treatment of meconium lung injury in rats. Biology of the Neonate 2005, 88:46-53.
27. Lukkarinen H., Laine J., Lehtonen J., Zagariya A., Vidyasagar D., Aho H., Kääpä P. Angiotensin II receptor blockade inhibits pneumocyte apoptosis in experimental meconium aspiration. Pediatric Research 2004, 55:326-333.
28. Mokra D., Mokry J. Glucocorticoids in the treatment of neonatal meconium aspiration syndrome. European Journal of Pediatrics 2011, 170:1495-1505.
29. Mokra D., Drgova A., Mokry J., Pullmann R., Redfors B., Petraskova M., Calkovska A. Comparison of the effects of low-dose vs. high-dose aminophylline on lung function in experimental meconium aspiration syndrome. Journal of Physiology and Pharmacology 2008, 59(6):449-459.
30. Mokra D., Tribulova E., Saffova I., Erneyova J., Calkovska A. Changes in surface activity of surfactant induced by in vitro exposure to meconium assessed by capillary surfactometer. Acta Medica Martiniana 2010, 10:13-18.
31. Mokra D., Drgova A., Pullmann R., Calkovska A. Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury. Pulmonary Pharmacology and Therapeutics 2012, 25:216-222.
32. Mokra D., Drgova A., Kopincova J., Pullmann R., Calkovska A. Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury. Advances in Experimental Medicine and Biology 2013, 756:189-196.
33. Möller J.C., Kohl M., Reiss I.I., Diederich W., Nitsche E.M., Göpel W., Gortner L. Saline lavage with substitution of bovine surfactant in term neonates with meconium aspiration syndrome (MAS) transferred for extracorporeal membrane oxygenation (ECMO): a pilot study. Critical Care 1999, 3:19-22.
34. Ochs M., Schüttler M., Stichtenoth G., Herting E. Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran. Respiratory Research 2006, 7:86.
35. Ohama Y., Ogawa Y. Treatment of meconium aspiration syndrome with surfactant lavage in an experimental rabbit model. Pediatric Pulmonology 1999, 28:18-23.
36. Pallem V., Kaviratna A.S., Chimote G., Banerjee R. Effect of meconium on surface properties of surfactant monolayers and liposomes. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2010, 370:6-14.
37. Rodríguez-Capote K., Manzanares D., Haines T., Possmayer F. Reactive oxygen species inactivation of surfactant involves structural and functional alterations to surfactant proteins SP-B and SP-C. Biophysical Journal 2006, 90:2808-2821.
38. Sáenz A., López-Sánchez A., Mojica-Lázaro J., Martínez-Caro L., Nin N., Bagatolli L.A., Casals C. Fluidizing effects of C-reactive protein on lung surfactant membranes: protective role of surfactant protein A. FASEB Journal 2010, 24:3662-3673.
39. Salvia-Roigés M.D., Carbonell-Estrany X., Figueras-Aloy J., Rodríguez-Miguélez J.M. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatrica 2004, 93:60-65.
40. Sevecova-Mokra D., Calkovska A., Drgova A., Javorka M., Javorka K. Treatment of experimental meconium aspiration syndrome with surfactant lung lavage and conventional vs. asymmetric high-frequency jet ventilation. Pediatric Pulmonology 2004, 38:285-291.
41. Stichtenoth G., Jung P., Walter G., Johansson J., Robertson B., Curstedt T., Herting E. Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatric Research 2006, 59:407-411.
42. Sun B., Curstedt T., Robertson B. Surfactant inhibition in experimental meconium aspiration. Acta Paediatrica 1993, 82:182-189.
43. Sun B., Curstedt T., Robertson B. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. American Journal of Respiratory and Critical Care Medicine 1996, 154:764-770.
44. Szymankiewicz M., Gadzinowski J., Kowalska K. Pulmonary function after surfactant lung lavage followed by surfactant administration in infants with severe meconium aspiration syndrome. Journal of Maternal-Fetal and Neonatal Medicine 2004, 16:125-130.
45. Taeusch W.H., Lu K.W., Goerke J., Clements J.A. Nonionic polymers reverse inactivation of surfactant by meconium and other substances. American Journal of Respiratory and Critical Care Medicine 1999, 159:1391-1395.
46. Tashiro K., Kobayashi T., Robertson B. Dextran reduces surfactant inhibition by meconium. Acta Paediatrica 2000, 89:1439-1445.
47. Walther F.J., Hernández-Juviel J.M., Mercado P.E., Gordon L.M., Waring A.J. Surfactant with SP-B and SP-C analogues improves lung function in surfactant-deficient rats. Biology of the Neonate 2002, 82:181-187.
48. Walther F.J., Waring A.J., Hernandez-Juviel J.M., Gordon L.M., Schwan A.L., Jung C.L., Chang Y., Wang Z., Notter R.H. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS ONE 2007, 2:e1039.
49. Yeh T.F., Lin H.C., Chang C.H., Wu T.S., Su B.H., Li T.C., Pyati S., Tsai C.H. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008, 121:e1310-e1318.
50. Zagariya A., Bhat R., Navale S., Chari G., Vidyasagar D. Inhibition of meconium-induced cytokine expression and cell apoptosis by pretreatment with captopril. Pediatrics 2006, 117:1722-1727.
51. Zuo Y.Y., Alolabi H., Shafiei A., Kang N., Policova Z., Cox P.N., Acosta E., Hair M.L., Neumann A.W. Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation. Pediatric Research 2006, 60:125-130.
52. Zuo Y.Y., Veldhuizen R.A., Neumann A.W., Petersen N.O., Possmayer F. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochimica et Biophysica Acta 2008, 1778:1947-1977.